Esplora contenuti correlati



SI.F.I. PA.CRO.DE. - Development and industrialization of innovative drugs for personalized molecular therapy - falls within an advanced sector of biomedical research for the development of biopharmaceuticals with innovative therapeutic characteristics for the treatment of chronic degenerative diseases and, in particular, oncological diseases (solid tumours, such as breast and ovarian cancers, and myelo- and lymphoproliferative disorders). In line with the personalized molecular medicine approach, innovative high throughput technologies will be used to develop molecules of interest for human health with multiple properties that improve their therapeutic efficacy and primary target selectivity. To this end, the project proposes a research, development and production chain for recombinant monoclonal antibody (rFab) fragments directed at known selective molecular targets, to be used to generate rFab2 conjugated to molecules that recognize two different targets in order to improve their selectivity and enhance their biological effect.
The tailored therapy technology will be used not only for drugs but also for nutraceuticals. The signature of the molecular and genomic effects of nutraceuticals will be identified in order to achieve an innovative integrated approach to neoplastic and chronic degenerative diseases.

Financial Resources
The project, lasting 30 months, was funded by the NOP Research and Innovation 2014-2020 within Axis II “Thematic Projects”, Action “Clusters” which finances industrial research and experimental development projects in the 12 specialization areas identified by the National Research Programme (PNR) 2015-2020, in particular in the “Health” specialization area. For the implementation of this initiative, a budget of 3.347.546,79 euro was allocated to the following beneficiaries forming the public-private partnership:

  • University of CALABRIA
  • BIOVIIIX srl
  • Biogenet
  • Okolab Srl
  • Charles River Laboratories Italia 

Impact on the Territory
The ambitious goal of developing biopharmaceuticals for the treatment of oncological diseases is expected to support the local social and economic fabric by generating new job opportunities and attracting investment and expertise to the target areas. In this regard, the project can create the conditions to attract, through targeted initiatives, investors/big pharma/centres of excellence interested in the exploitation of the project results and enhance the network and collaborations between academic and industrial researchers.
The southern regions involved will be able to become key players in a technology innovation process in the oncology sector while improving the competitiveness of their industrial sector and of their human capital.

torna all'inizio del contenuto